特尔尼翁钢铁 TX 深 沪
已收盘 08-08 16:00:00 美东时间
32.00
+0.740
+2.37%
华盛通- 最 高32.11
- 今 开31.47
- 成交量 18.99万股
- 最 低 31.35
- 昨 收 31.26
- 总市值 62.72亿
- 52周最高 35.28
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 22.20
- 委 比 9.91%
- 总股本 1.96亿
- 历史最高 45.56
- 量 比 1.05
- 振 幅 2.43%
- 历史最低 -7.32
- 每 手 1
- 风险率 2.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Blockchain Meets The Stratosphere: World Mobile Launches High-Altitude Connectivity Aircraft With Protelindo
World Mobile partners with Protelindo to launch new stratospheric platform using blockchain and high-altitude aircraft for global connectivity.
08-09 00:07
SkyWater Technology Sees Q3 GAAP EPS $(0.28)-$(0.22) vs $(0.04) Est
Q3 2025 Financial Outlook:Our current expectations of third-quarter financial results reflect the following low-end to high-end of these ranges:Wafer Services revenue Wafer Services revenue
08-07 04:27
WESTERN MIDSTREAM ANNOUNCES SECOND-QUARTER 2025 RESULTS
EXECUTING ON CORE GROWTH STRATEGY AND REAFFIRMING 2025 FINANCIAL GUIDANCE RANGES Reported second-quarter 2025 Net income attributable to limited partners of $333.8 million, generating record...
08-07 04:07
TSS Reports Second Quarter 2025 Revenue of $44.0 Million
Georgetown Facility Fully Operational, Positioning Company to Accelerate Throug...
08-07 04:05
WESTERN MIDSTREAM TO ACQUIRE ARIS WATER SOLUTIONS
Creates a differentiated Delaware Basin produced-water system, enhancing WES's ability to compete for new business development opportunities. The combined infrastructure creates a fully inte...
08-07 04:05
Crescita Therapeutics Q2 EPS $0.04 Up From $(0.05) YoY, Sales $6.233M Up From $4.088M YoY
Crescita Therapeutics (TSX:CTX) reported quarterly earnings of $0.04 per share. This is a 180 percent increase over losses of $(0.05) per share from the same period last year. The company reported $6.233 million in
08-06 20:45
中指研究院商业地产月报：7月监测到1亿元以上大宗交易12宗 二季度消费REITs底层资产运营稳健
2025年1-7月，300城商办用地推出及成交规划建筑面积分别为12663万平方米、10297万平方米。
08-05 19:33
Shattuck Labs Secures Up To $103M In Private Placement Financing Through Securities Purchase Agreement
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –– Pro forma cash and cash equivalents
08-05 18:37
TX Rail Products reports FQ3 results
TX Rail Products press release (OTCPK:TXRP): FQ3 Net income was $297,000 Revenue of $1.9M (+5.6% Y/Y). More on TX Rail Products Financial information for TX Rail Products
08-05 06:06
What's Next: Ocular Therapeutix's Earnings Preview
Ocular Therapeutix (NASDAQ:OCUL) will release its quarterly earnings report on ...
08-05 04:04
